Similar to excellent results achieved in advanced patients, none of patients enrolled in our study had CNS metastasis during the treatment of alectinib, which indicated that adjuvant alectinib may reduce the risk of CNS recurrence among patients with resected ALK-positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.